Cancer Drug Zevalin May Finally Thrive Under Spectrum
This article was originally published in The Pink Sheet Daily
The small oncology company may be able to succeed with the non-Hodgkin lymphoma drug where others have failed.
You may also be interested in...
FDA citations of Rituxan comparisons in a promotion for Zevalin throw added salt on old wounds for drug that has taken backseat to Rituxan’s blockbuster story.
The radiotherapeutics sector is attracting a new and diverse group of biopharma players hoping to capitalize on the potential advantages offered by newer therapeutic radioisotopes.
Spectrum issued a tender offer of $1.82 per share for Allos Therapeutics on the same day that it announced the Phase III failure of its bladder cancer drug.